Skip to content Inauguração emGrand opening inInauguración en --d --h --m --s · Cadastro VIP ›· VIP sign-up ›· Registro VIP › Abrimos hoje · aguardeWe open today · hold onAbrimos hoy · aguarde Loja aberta! Entrar ›Store open! Enter ›¡Tienda abierta! Entrar ›
Eagle Pharma
Track order WhatsApp

KNOWLEDGE · COMPOUNDS

NAD+

LongevityClinical trialsPubMed records: 500count from PubMed, not curated
Ask Eagle AI about this compound

Overview

O NAD+ (Nicotinamida Adenina Dinucleotídeo) é uma coenzima presente em todas as células vivas, essencial para a produção de energia celular (ATP), ativação de sirtuínas (genes de longevidade), reparo de DNA (via PARPs) e centenas de reações metabólicas. Os níveis de NAD+ diminuem ~50% entre os 40 e 60 anos, contribuindo para o declínio energético, acúmulo de dano ao DNA e envelhecimento celular. A reposição direta via injeção restaura os níveis celulares de forma mais eficiente que precursores orais (NMN, NR). Original in PT-BR

NAD+ is catalogued under Longevity. 1 Eagle article in this library references this compound.

Category
Longevity
Research stage
Clinical trials — Ensaios Clínicos (Precursores NMN/NR) Original in PT-BR
PubMed records
500 (count from PubMed, not curated)
Eagle articles on this compound
1 Eagle article

Mechanism

Coenzima central do metabolismo energético — cofator de sirtuínas (longevidade) e PARPs (reparo DNA) Original in PT-BR

O NAD+ atua como cofator em três famílias enzimáticas críticas: (1) SIRTUÍNAS (SIRT1-7): deacetilases dependentes de NAD+ que regulam expressão gênica, metabolismo, inflamação e reparo celular — são os principais mediadores de longevidade. (2) PARPs: enzimas de reparo de DNA que consomem NAD+ para corrigir quebras de fita dupla e dano oxidativo. (3) CD38/CD157: enzimas do sistema imune que consomem NAD+ crescentemente com a idade (principal causa do declínio). Além disso, NAD+ é essencial na cadeia respiratória mitocondrial (NADH → NAD+) para produção de ATP. Original in PT-BR

Eagle articles on this compound

Chemical information

CAS
53-84-9
Molecular formula
C₂₁H₂₇N₇O₁₄P₂
Molecular weight
663.43 g/mol
Sequence
Dinucleotídeo (não é peptídeo — é coenzima) Original in PT-BR
Amino acids
Not recorded in the source.
Solubility
Altamente solúvel em água Original in PT-BR
Stability
Reconstituído: 7-14 dias 2-8°C. Sensível a luz e calor Original in PT-BR
Half-life
Variável (depende de via e tecido) Original in PT-BR
Bioavailability
Alta (SC), Imediata (IV) Original in PT-BR
Onset
Horas (energia), semanas (benefícios sistêmicos) Original in PT-BR
Routes
SC · IV

Research references

No individual dosing recommendation is given. Values are as recorded in the source, with species and route stated where known.

Third-party research score

85/ 100

Score assigned by the imported source, on its own scale and with no published methodology. Eagle does not compute it, does not verify it and does not endorse it. It appears here to preserve the record, not as an assessment.

  • Estabeleceu declínio de NAD+ como causa central do envelhecimento celular Original in PT-BR

    PMID: 24786309Year: 2014Species: Not recorded as a structured field in the source.Route: Not recorded as a structured field in the source.Duration: Not recorded as a structured field in the source.Purpose: Not recorded as a structured field in the source.

  • Ensaio clínico mostrou que NMN eleva NAD+ sérico de forma segura Original in PT-BR

    PMID: 29514064Year: 2018Species: Not recorded as a structured field in the source.Route: Not recorded as a structured field in the source.Duration: Not recorded as a structured field in the source.Purpose: Not recorded as a structured field in the source.

  • Revisão abrangente do eixo NAD+/sirtuínas na longevidade Original in PT-BR

    PMID: 26785480Year: 2015Species: Not recorded as a structured field in the source.Route: Not recorded as a structured field in the source.Duration: Not recorded as a structured field in the source.Purpose: Not recorded as a structured field in the source.

  • NAD+ protege contra disfunção cardiovascular associada ao envelhecimento Original in PT-BR

    PMID: 30082460Year: 2018Species: Not recorded as a structured field in the source.Route: Not recorded as a structured field in the source.Duration: Not recorded as a structured field in the source.Purpose: Not recorded as a structured field in the source.

Safety

Commonly reported

  • Flush facial (especialmente IV rápido)
  • Náusea leve
  • Aperto no peito transitório
  • Formigamento

Serious

  • Reações intensas se a infusão IV for mais rápida que 45 min para 1000mg
  • Bem tolerado SC

Contraindications

  • Hipersensibilidade

Warnings

  • IV deve ser lento (mínimo 45-60 min para 1000mg)
  • SC causa menos efeitos colaterais que IV

Original in PT-BR — This text was written in Brazilian Portuguese and is shown as recorded. Open the PT-BR page for NAD+.

Lab tests named in the source

  • NAD+ sérico (se disponível)
  • ALT/AST (fígado)
  • Hemograma
  • PCR

The source names the tests and nothing else: no reference values and no thresholds. None were added here. Interpreting a result is a clinical act and is not offered on this page.

Reported protocols

Recorded in the imported source as community protocols. They are NOT Eagle protocols, were not reviewed by Eagle, and are not a dosing recommendation, a prescription or clinical guidance. Values appear exactly as recorded, in the language they were written in.

Dosing summary as recorded

Dose SC
250-500mg, 3-4x/semana Original in PT-BR
Dose IV
500-1000mg semanal (lento) Original in PT-BR
Via preferida
SC (menos efeitos colaterais) Original in PT-BR
Seringa
Seringa de 1mL (não insulina para volumes altos) Original in PT-BR

Vial sizes: 1000mg

Interactions

These relations come from the imported reference material, which records one label and one comment per pair and no source: no PMID, no population or model, no evidence type and no degree of certainty. Eagle did not verify them and does not endorse them. «Compatible», «Caution» and «Avoid» are the imported material's wording, not an Eagle authorisation or prohibition, and none of this is medical advice.

Reported synergy

Compatible

Related

  • NAD+Experimental protocol
← Back to knowledge area